Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04687059 · ClinicalTrials.gov registry record · Phase 2
An Exploratory Study of PQ Grass 27600 SU
A Phase 2 study, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT04687059 is a Phase 2 study that has completed, run by Allergy Therapeutics. The registered enrollment target is 119 participants.
The verdict
NCT04687059, a Phase 2 study, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting. The study will enrol adult subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure.
Interventions
- DRUG Active Placebo
- BIOLOGICAL PQ Grass
- DRUG Standard Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2021-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04687059
The ClinicalTrials.gov registry entry for NCT04687059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Active Placebo is the first listed.
NCT04687059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04687059 about?
NCT04687059 is a clinical study titled "An Exploratory Study of PQ Grass 27600 SU". PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting. The study will enrol adult subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure.
What is the current status of trial NCT04687059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2020-10-19. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT04687059?
The interventions under investigation include: Active Placebo (DRUG), PQ Grass (BIOLOGICAL), Standard Placebo (DRUG).
Who is sponsoring clinical trial NCT04687059?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.